Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03522142
Recruitment Status : Recruiting
First Posted : May 11, 2018
Last Update Posted : March 24, 2020
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: INCB081776 Drug: INCMGA00012 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Actual Study Start Date : May 24, 2018
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : October 31, 2020

Arm Intervention/treatment
Experimental: INCB081776
Single-agent INCB081776.
Drug: INCB081776
INCB081776 administered once daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.

Experimental: INCB081776 + INCMGA00012
INCB081776 in combination with INCMGA00012.
Drug: INCB081776
INCB081776 administered once daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.

Drug: INCMGA00012
INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
Other Name: retifanlimab




Primary Outcome Measures :
  1. Part 1 and Part 2: Number of treatment-emergent adverse events (TEAEs) [ Time Frame: Screening through 90 days after end of treatment, up to approximately 1 year. ]
    A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.


Secondary Outcome Measures :
  1. Part 1 and Part 2: Cmax of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Maximum observed plasma concentration.

  2. Part 1 and Part 2: Tmax of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Time to maximum plasma concentration.

  3. Part 1 and Part 2: t½ of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Apparent plasma terminal phase disposition half-life

  4. Part 1 and Part 2: Pharmacokinetic/ pharmacodynamic correlation [ Time Frame: Up to approximately 3 weeks. ]
    To evaluate the correlation pharmacokinetic and pharmacodynamics of INCB081176

  5. Part 1 and Part 2: Overall response rate [ Time Frame: Up to approximately 1 year. ]
    Defined as the percentage of participants having complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

  6. Part 1 and Part 2: Disease control rate [ Time Frame: Up to approximately 1 year. ]
    Defined as the percentage of participants having CR, PR, or stable disease (SD) per RECIST v1.1.

  7. Part 1 and Part 2: Duration of response [ Time Frame: Up to approximately 1 year. ]
    Defined as the time from earliest date of disease response until the earliest date of disease progression (per RECIST v1.1) or death due to any cause, if occurring sooner than progression.

  8. Part 1 and Part 2: AUC0-t of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration

  9. Part 1 and Part 2: Cmin of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Trough concentration of INCB081776

  10. Part 1 and Part 2: AUC0-∞ of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Area under the single-dose plasma concentration-time curve from Hour 0 to infinity

  11. Part 1 and Part 2 : CL/F of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Oral dose clearance

  12. Part 1 and Part 2 : λz of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Terminal elimination rate constant

  13. Part 1 and Part 2 : Vz/F of INCB081776 [ Time Frame: Up to approximately 3 weeks. ]
    Apparent oral dose volume of distribution



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Male and female participants at least 18 years of age with advanced malignancies who have received or been intolerant to standard therapy:

Parts 1A and 2A:

  • Histologically confirmed advanced or metastatic gastric or GEJ adenocarcinoma, HCC, melanoma, NSCLC, RCC, soft-tissue sarcoma, SCCHN (recurrent or metastatic), TNBC, or urothelial carcinoma. Additional tumor histologies, including MSI-H tumors, may be allowed with approval from the medical monitor.
  • Measurable disease per RECIST v1.1.

Parts 1B and 2B:

• Histologic confirmation of the cohort-specific tumor types specified below: Cohort 1 - Advanced or metastatic melanoma Cohort 2 - Advanced or metastatic NSCLC Cohort 3 - Recurrent or metastatic SCCHN Cohort 4 - Advanced or metastatic soft-tissue sarcoma

  • Cohorts 1-3 must have received 1 prior PD-1/L1 treatment and have experienced PD during or after that treatment and have progressed on other SOC therapy(ies); Cohort 4 must be PD-1/L1 treatment naïve but have progressed on SOC therapy(ies).
  • Measurable disease per RECIST v1.1.
  • Must be willing to submit to a fresh baseline tumor biopsy and an on-treatment biopsy between Cycle 2 Day 1 and Cycle 3 Day 1.
  • Care should be taken to biopsy the same lesion for the baseline and on-treatment samples. If a participant has a solitary target lesion, this should not be biopsied.

Part 1C:

  • Participants with relapsed/refractory AML following standard therapy; acute promyelocytic leukemia (M3) and therapy-related AML are excluded.
  • FLT3-ITD and IDH1/2 wild-type or mutated are eligible; appropriate targeted therapy for participants with actionable mutations must have been received.

Exclusion Criteria:

  • Laboratory values not within the protocol-defined range.
  • History of retinal disease as defined in the protocol.
  • Clinically significant cardiac disease as per protocol-defined criteria.
  • History or presence of an ECG that, in the investigator's opinion, is clinically meaningful as per protocol-defined criteria.
  • Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed as per protocol-defined criteria.
  • Active or inactive autoimmune disease or syndrome that has required systemic treatment in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory disease.
  • Prior Grade 3 or higher immune-related AEs or any ocular toxicity on prior immunotherapy as per protocol-defined criteria.
  • Receipt of any vitamin K antagonists, systemic corticosteroids, live vaccines, or treatment with any anticancer medications or investigational drugs within the protocol-defined intervals.
  • Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment.
  • Active infection requiring systemic therapy.
  • Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
  • Known history of HIV (HIV 1/2 antibodies).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03522142


Contacts
Layout table for location contacts
Contact: Incyte Corporation Call Center (US) 1.855.463.3463 medinfo@incyte.com

Locations
Layout table for location information
United States, Connecticut
Yale Cancer Center Recruiting
New Haven, Connecticut, United States, 06510
Principal Investigator: Patricia LoRusso, MD         
United States, Massachusetts
Dana Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02215
Principal Investigator: Geoffrey Shapiro, MD         
United States, New York
Memorial Sloan Kettering Cancer Center Withdrawn
New York, New York, United States, 10065
United States, Pennsylvania
University of Pennsylvania Abramson Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Principal Investigator: Tara Mitchell, MD         
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Principal Investigator: James Lee, MD         
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Principal Investigator: Melissa Johnson, MD         
Sponsors and Collaborators
Incyte Corporation
Investigators
Layout table for investigator information
Study Director: Diane Hershock, MD Incyte Corporation

Layout table for additonal information
Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT03522142    
Other Study ID Numbers: INCB 81776-101
First Posted: May 11, 2018    Key Record Dates
Last Update Posted: March 24, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
Advanced solid tumors
AXL
MER
AXL/MER
PD-1
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms